Prelude Therapeutics Inc (PRLD)

Pharmaceutical Preparations · market cap $354M · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-11 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Prelude Therapeutics (PRLD) is a small-cap oncology company with 131 employees and a ~$408M market cap, built around a single clinical asset, PRT3789, currently in Phase 2 for advanced solid tumors. The company is in acute financial distress, with only $21.8M in cash and an estimated runway of approximately three months, making near-term financing a near-certainty.

The catalyst path

2026-11-11 (est.)Earningsimp 5/10
2027-08-15 (est.)Phase 2 · PRT3789imp 7/10

Pipeline

Asset	Phase	Indication
PRT3789	Phase 2	Advanced Solid Tumor

Price & technical context

3-month

-25.3%

6-month

+7.8%

12-month

+147.0%

52-wk range

$1.19–$6.63

vs 50-day MA

-25.2%

vs 200-day MA

-4.0%

Realized vol

167.2%

Max drawdown

-88.7%

Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for PRLD (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.